How do I tell nausea from an energy deficit on 900 kcal a day?

Concretely: nausea · 900 kcal.

I have two candidate explanations and no way to distinguish them.

The same procedure has worked without incident several times previously, which argues against technique.

How do I distinguish the benign explanation from the one that matters?

The honest framing is that this is very common, usually self-limiting, and occasionally the presentation of something that is not self-limiting at all — and the differentiating features are specific enough to be worth knowing.

Early satiety is not a side effect; it is the mechanism being observable. The useful distinction is between satiety, where you stop eating without distress, and aversion, where the thought of food is unpleasant. The first is the intended effect. The second frequently precedes the dose being too high or escalated too fast.

Vomiting matters mostly through its consequences. Loss of gastric fluid depletes sodium, chloride and potassium, and hypokalaemia presents as exactly the fatigue and cramping people attribute to the drug. Persistent vomiting also makes a renal panel uninterpretable, because a pre-renal picture looks like renal impairment.

The pooled gastrointestinal adverse-event rates across the STEP programme and the SURMOUNT programme are reported in the primary publications and in the FDA and EMA assessment reports, and the assessment reports are more useful because they give the placebo-arm rates alongside the active-arm rates in the same table.

Worth being explicit: nothing here is medical advice, and research-use-only compounds are not approved for human use.

Write down in advance which symptoms mean stop and seek care. It is a short list and it is much easier to write when you are well.

edited 11 Mar 2025 by ahmed_zerouali — fixed an arithmetic slip in the third paragraph

The mechanism explains the pattern. Delayed gastric emptying plus central appetite suppression produces early satiety, and early satiety plus a slowed transit produces exactly the symptom cluster people report.

Pancreatitis red flags worth memorising rather than looking up: severe, persistent epigastric pain radiating to the back, worse lying flat and better sitting forward, with nausea and vomiting that does not settle. That combination is an urgent assessment, not a dose adjustment. An isolated lipase elevation without that picture is common and usually not pancreatitis.

Nausea incidence in the pivotal trials runs to roughly 40 to 45 per cent at the higher doses against 15 to 20 per cent on placebo, with vomiting at roughly 15 to 25 per cent against 5 to 8 per cent. Discontinuation specifically attributable to gastrointestinal adverse events was in the range of 4 to 7 per cent. Those are the numbers to hold in mind when someone describes their experience as unusual.

Telogen effluvium following substantial weight loss is documented independently of any pharmacotherapy, which is the cleanest argument that the rate of loss rather than the agent is the primary driver.

The limitation of the timing heuristic is that it works well for common events and poorly for rare ones, which are precisely the ones that matter most.

Most of this resolves. The point of knowing the pattern is to recognise the small fraction that does not.

Mechanically, look at the placebo arm before concluding anything about attribution. The placebo-arm rates for most of these events are not small, because the events themselves are common in the underlying population.

The gallbladder signal tracks the rate of weight loss more than it tracks the drug. Rapid mobilisation of adipose tissue increases biliary cholesterol saturation and reduces gallbladder motility; that combination is lithogenic whether the loss came from a drug, a very-low-energy diet or bariatric surgery. The drug contribution on top of that is present but smaller than the rate contribution.

Pooled analyses of gallbladder-related events with GLP-1 receptor agonists find a modest increase in relative risk, with the effect larger at higher doses and longer durations — consistent with a rate-of-loss mechanism as much as a direct one[1].

A symptom diary with dates against dose steps answers most of these questions without anyone needing to guess.

The distinction worth making early is between a tolerability problem, which is unpleasant and self-limiting, and a clinical problem, which is neither. They present differently and the thresholds for each are worth writing down before you need them.

Fatigue attribution is a subtraction problem. Take out the energy deficit, the dehydration, the electrolyte shortfall and the poor sleep, and what remains attributable to the drug in the trials was modest — placebo-arm fatigue rates were within a few points of active-arm rates in most of the programme. The corollary is that the fixable causes are usually the actual causes.

The caveat that actually matters: this is pattern recognition from published data, not a clinical assessment of you. Anything severe, persistent or accompanied by systemic features belongs with a clinician the same day.

If the timing does not fit the escalation, look for another explanation before settling on the drug.